Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Tesetaxel as Second-line Therapy for Subjects With Advanced Melanoma and Normal Serum LDH

NCT01092585 is registered in ClinicalTrials.gov with Genta Incorporated as lead sponsor.

NCT NCT01092585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01092585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Tesetaxel as Second-line Therapy for Subjects With Advanced Melanoma and Normal Serum LDH
Lead sponsor
Genta Incorporated
Phase
Phase 2
Overall status
Unknown status
Start date
February 28, 2010
Completion date
March 31, 2012
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma